TMCnet News

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
[August 31, 2021]

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference


DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting Monday, September 13, at 7:00 A.M. (ET).

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 9 days.



About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.


CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
[email protected] 

For Media
Andrea Greif
Ogilvy
[email protected]
914-772-3027


Primary Logo


[ Back To TMCnet.com's Homepage ]